Prof. Markku Nieminen

Prof. Markku Nieminen is a distinguished professor of cardiology at the University of Helsinki and a senior consultant at Helsinki University Hospital (HUCH) — Finland's largest and most complex hospital and one of Scandinavia's foremost academic medical centres. Over a career of more than 35 years, he has established himself as one of Europe's leading experts in acute heart failure and cardiovascular intensive care, combining a high-volume clinical practice with a research programme that has produced landmark trials and shaped international guidelines.

HUSCH serves as Finland's national referral centre for the most complex cardiac cases, and Prof. Nieminen has been instrumental in developing its cardiac intensive care and heart failure management programmes. His practice encompasses the emergency management of acutely decompensated heart failure and cardiogenic shock — the most dangerous presentations of cardiac disease — as well as the longer-term outpatient management of chronic heart failure and cardiomyopathy.

Prof. Nieminen is perhaps best known internationally for his central role in the SURVIVE trial, a landmark randomised clinical trial comparing levosimendan — a calcium sensitiser and vasodilator with inotropic properties — against dobutamine in the treatment of acute decompensated heart failure. The SURVIVE trial, published in JAMA, was a defining study in the pharmacological management of acute heart failure and stimulated extensive subsequent investigation into the optimal haemodynamic support strategies for critically ill cardiac patients.

Beyond SURVIVE, Prof. Nieminen has led or participated in the REVIVE trials and has been a driving force in the EuroHeart Failure Survey, one of the largest pan-European observational studies of acute heart failure management and outcomes, which provided invaluable data on how heart failure patients are managed and how their outcomes vary across European healthcare systems.

Prof. Nieminen completed his medical degree at the University of Helsinki Faculty of Medicine, one of Finland's leading medical schools and a major European research institution. He undertook postgraduate specialty training in internal medicine and cardiology at Helsinki University Hospital, developing broad expertise in both general cardiology and cardiac intensive care during an era when the discipline was undergoing rapid transformation.

He earned his PhD for research examining haemodynamic and neurohormonal mechanisms in heart failure — work that established the conceptual foundations for his subsequent focus on inotropic therapy and haemodynamic support in acute heart failure. He developed advanced skills in right heart catheterisation and haemodynamic monitoring, which became central to his management of complex acute heart failure cases.

Prof. Nieminen holds Fellowship of the European Society of Cardiology (FESC) and has served on the ESC's Acute Cardiovascular Care Association (ACCA) and Heart Failure Association working groups and guideline committees. He holds a full professorship at the University of Helsinki and has supervised numerous doctoral researchers in cardiovascular physiology and pharmacology.

Prof. Nieminen's primary clinical focus is the management of acute and chronic heart failure across its full spectrum of severity. In the acute setting, he specialises in the haemodynamic assessment and pharmacological stabilisation of patients with acute decompensated heart failure and cardiogenic shock — conditions requiring rapid, precise clinical decision-making and expert use of vasodilatory, diuretic, and inotropic therapies.

His procedural expertise includes comprehensive echocardiographic assessment of ventricular structure and function, right heart catheterisation for invasive haemodynamic profiling, and the use of intravenous inotropes (dobutamine, levosimendan, milrinone) and vasopressors in the cardiac intensive care setting. He also manages patients on mechanical ventilation and has experience with temporary mechanical circulatory support.

In chronic heart failure management, Prof. Nieminen is an expert in the optimisation of guideline-directed medical therapy — including ACE inhibitors/ARBs/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — and in the management of heart failure with preserved ejection fraction (HFpEF), an increasingly prevalent but therapeutically challenging condition. He also has expertise in the diagnosis and management of myocarditis and inflammatory cardiomyopathies.

Prof. Nieminen has authored over 250 peer-reviewed publications in journals including JAMA, the European Heart Journal, the Journal of the American College of Cardiology (JACC), Circulation, and the European Journal of Heart Failure. His work spans clinical trial design, haemodynamic physiology, and epidemiological outcome research in heart failure.

The SURVIVE trial (2007, JAMA) stands as his most celebrated individual research contribution. This 1,327-patient international randomised controlled trial compared levosimendan against dobutamine in patients hospitalised with acute decompensated heart failure, finding no significant difference in all-cause mortality at 180 days — but providing crucial safety and efficacy data that inform the use of both agents in clinical practice today.

The REVIVE trials (REVIVE I and REVIVE II), to which he also contributed, further characterised the clinical effects of levosimendan in acute heart failure. His leadership of the EuroHeart Failure Survey, which collected data on over 10,000 acute heart failure patients across 133 European hospitals, produced landmark epidemiological findings that directly influenced the development of ESC acute heart failure guidelines. He has served on the writing committees for multiple ESC Heart Failure Guidelines.

Prof. Nieminen consults in Finnish, Swedish, and English, and HUCH welcomes international referrals for complex heart failure cases and second opinions. Helsinki is well-connected to other Scandinavian capitals and European cities, making HUCH accessible for patients from across the Nordic region and beyond.

EU/EEA patients may be eligible for cross-border healthcare funding when accessing specialised heart failure services at HUCH. Non-EU patients are seen on a private referral basis, and the hospital's international patient office can assist with coordination. For patients with acute or rapidly deteriorating heart failure referred from other Scandinavian countries, urgent consultation pathways are available.

Telemedicine consultations are available for patients and their cardiologists who wish to discuss complex heart failure management decisions, optimal inotrope strategies, or cardiomyopathy workup. Prof. Nieminen's multilingual capability (Finnish, Swedish, English) is a particular asset for patients from Finland's Swedish-speaking minority and from neighbouring Sweden.

Prof. Nieminen has been recognised by the Finnish Cardiac Society (FCS) as a Distinguished Fellow in recognition of his sustained contributions to Finnish cardiology. He is a Fellow of the European Society of Cardiology (FESC) and has served on multiple ESC working groups and guideline committees for heart failure and acute cardiovascular care.

The Finnish Medical Association has honoured him with its Research Award for outstanding contributions to cardiovascular research and evidence-based clinical practice in Finland. He is a sought-after invited lecturer at ESC Heart Failure congresses, ACCA meetings, and other international forums. His extensive experience as a clinical trial leader — including the SURVIVE trial and EuroHeart Failure Survey — has made him a valued advisor for the design of subsequent acute heart failure trials in Europe.